The expression of PD-L1 across a spectrum of non-small-cell lung cancers (NSCLC) of varying KRAS mutant isoforms is predictive of responses to immune checkpoint inhibitors in a similar fashion to wild-type NSCLC [37]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.